Arthur Tzianabos - Net Worth and Insider Trading

Arthur Tzianabos Net Worth

The estimated net worth of Arthur Tzianabos is at least $385,247 dollars as of 2024-11-05. Arthur Tzianabos is the Director of Q32 Bio Inc and owns about 7,983 shares of Q32 Bio Inc (QTTB) stock worth over $378,554. Arthur Tzianabos is the Director of Homology Medicines Inc and owns about 7,154 shares of Homology Medicines Inc (FIXX) stock worth over $6,687. Arthur Tzianabos is also the President and CSO of Millendo Therapeutics Inc and owns about 6 shares of Millendo Therapeutics Inc (MLND) stock worth over $6. Besides these, Arthur Tzianabos also holds Stoke Therapeutics Inc (STOK) . Details can be seen in Arthur Tzianabos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arthur Tzianabos has not made any transactions after 2024-03-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Arthur Tzianabos

To

Arthur Tzianabos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arthur Tzianabos owns 6 companies in total, including Akouos Inc (AKUS) , Stoke Therapeutics Inc (STOK) , and Homology Medicines Inc (FIXX) among others .

Click here to see the complete history of Arthur Tzianabos’s form 4 insider trades.

Insider Ownership Summary of Arthur Tzianabos

Ticker Comapny Transaction Date Type of Owner
AKUS Akouos Inc 2020-06-25 director
STOK Stoke Therapeutics Inc 2021-02-19 director
FIXX Homology Medicines Inc 2024-01-09 director & President & CEO
LIMIT LIMIT 2016-08-26 director
LIMIT LIMIT 2015-12-03 President and CSO
LIMIT LIMIT 2013-09-03 Chief Scientific Officer

Arthur Tzianabos Latest Holdings Summary

Arthur Tzianabos currently owns a total of 4 stocks. Among these stocks, Arthur Tzianabos owns 7,983 shares of Q32 Bio Inc (QTTB) as of March 25, 2024, with a value of $378,554 and a weighting of 98.26%. Arthur Tzianabos owns 7,154 shares of Homology Medicines Inc (FIXX) as of January 9, 2024, with a value of $6,687 and a weighting of 1.74%. Arthur Tzianabos also owns 6 shares of Millendo Therapeutics Inc (MLND) as of April 9, 2015, with a value of $6 and a weighting of 0%. The other 1 stocks Stoke Therapeutics Inc (STOK) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Arthur Tzianabos

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
QTTB Q32 Bio Inc 2024-03-25 7,983 47.42 378,554
FIXX Homology Medicines Inc 2024-01-09 7,154 0.93 6,687
MLND Millendo Therapeutics Inc 2015-04-09 6 1.06 6
STOK Stoke Therapeutics Inc 2021-02-19 0 12.61 0

Holding Weightings of Arthur Tzianabos


Arthur Tzianabos Form 4 Trading Tracker

According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 1 transactions in Q32 Bio Inc (QTTB) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Q32 Bio Inc is the sale of 265 shares on March 25, 2024, which brought Arthur Tzianabos around $6,413.

According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 6 transactions in Homology Medicines Inc (FIXX) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Homology Medicines Inc is the sale of 724 shares on January 9, 2024, which brought Arthur Tzianabos around $7,431.

According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 0 transactions in Millendo Therapeutics Inc (MLND) over the past 5 years. The most-recent trade in Millendo Therapeutics Inc is the acquisition of 1 shares on April 9, 2015, which cost Arthur Tzianabos around $6,473.

More details on Arthur Tzianabos's insider transactions can be found in the Insider Trading History of Arthur Tzianabos table.

Insider Trading History of Arthur Tzianabos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Arthur Tzianabos Trading Performance

GuruFocus tracks the stock performance after each of Arthur Tzianabos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arthur Tzianabos is -10.16%. GuruFocus also compares Arthur Tzianabos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arthur Tzianabos within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Arthur Tzianabos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Arthur Tzianabos

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -9.76 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -11.1 LIMIT LIMIT LIMIT LIMIT LIMIT

Arthur Tzianabos Ownership Network

Ownership Network List of Arthur Tzianabos

No Data

Ownership Network Relation of Arthur Tzianabos

Insider Network Chart

Arthur Tzianabos Owned Company Details

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Arthur Tzianabos is the director of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Akouos Inc Insider Transactions

No Available Data

Arthur Tzianabos Mailing Address

Above is the net worth, insider trading, and ownership report for Arthur Tzianabos. You might contact Arthur Tzianabos via mailing address: C/o Homology Medicines, Inc., One Patriots Park, Bedford Ma 01730.